Latest news

As of 1 February 2024, the federal government approved subcutaneous natalizumab (Tysabri®) for individuals with relapsing remitting MS (RRMS) under the Pharmaceutical Benefits Scheme (PBS).

People make countless decisions every day. They can be deeply personal and are often informed by your values, your experiences and people closest to you.

With Easter just around the corner, it's time to embrace the festivities while keeping our wellbeing in mind. Here are some evidence-based tips from a Dietitian for a healthful and joyful Easter.

Susan Hyde has stepped up to the plate for Western Australia, becoming the state representative in the MS Australia National Advocates Program.

For most, one diagnosis in a lifetime can, understandably, be more than enough for a person to handle.

One of the most frightening words in the English language is ‘potential’.

MSWA Clients are invited to submit their pieces of art for the chance to be part of the inaugural MSWA art exhibition.

MSWA is delighted to announce the appointment of Devlyn Construction as the chosen contractor for the development of its cutting-edge high-support accommodation facility in Shenton Park, Perth.

A world-leading clinical trial will seek to reverse neurological damage caused by primary progressive multiple sclerosis (PPMS) in Australians living with the debilitating condition, in an announcement made today at the MS Australia Progress in Research Conference in Perth.

In May, hairdresser Shanae Wilson transformed her Wangara salon into a fundraising hub – offering patrons blow outs and hair styling services, with 100% of the proceeds donated to MSWA.